First ALS Patient Enters US Study of Radicava's Impact on Disease Biomarkers
 

First ALS Patient Enters US Study of Radicava's Impact on Disease Biomarkers

First ALS Patient Enters US Study of Radicava's Impact on Disease Biomarkers

If I understand the medical argument underlying the Radicava strategy, the hypothesis is patients with the Amyotrophic Lateral Sclerosis syndrome may have suffered small stroke in their life without realization. Radicava is know to have positive effects in stroke patients . . . these positive effects might have collateral benefit(s) in Amyotrophic Lateral Sclerosis patients . . . possibly only because they indeed had stroke(s).